Patents Assigned to Research Corporation Technologies, Inc.
  • Patent number: 9051357
    Abstract: The present invention provides modified fibronectin type III (Fn3) molecules, and nucleic acid molecules encoding the modified Fn3 molecules. Also provided are methods of preparing these molecules, and kits to perform the methods.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: June 9, 2015
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Shohei Koide
  • Patent number: 8883445
    Abstract: The present invention provides genetically engineered strains of methylotrophic yeast including Pichia and especially Pichia pastoris capable of producing proteins with reduced or modified glycosylation. Methods of producing glycoproteins with reduced and/or modified glycosylation using such genetically engineered strains of Pichia are also provided. Vectors, which comprise coding sequences for ?-1,2-mannosidase I, glucosidase II, GlcNAc-tranferase I and mannosidase II or comprising OCH1 disrupting sequence, for transforming methylotrophic yeasts are contemplated by the present invention. Kit for providing the comtemplated vectors are also included in this invention.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: November 11, 2014
    Assignees: Research Corporation Technologies, Inc., Universiteit Gent, Vib, VZW
    Inventors: Roland Contreras, Nico L. M. Callewaert, Steven C. J. Geysens, Vladimir Kaigorodov, Vervecken Wouter
  • Publication number: 20140221251
    Abstract: Viable Gram-negative bacteria or components thereof comprising outer membranes that substantially lack a ligand, such as Lipid A or 6-acyl lipidpolysaccharide, that acts as an agonist of TLR4/MD-2. The bacteria may comprise reduced activity of arabinose-5-phosphate isomerases and one or more suppressor mutations, for example in a transporter thereby increasing the transporter's capacity to transport lipid IVA or in membrane protein YhjD. One or more genes (e.g., lpxL, lpxM, pagP, lpxP, and/or eptA) may be substantially deleted and/or one or more enzymes (e.g., LpxL, LpxM, PagP, LpxP, and/or EptA) may be substantially inactive. The bacteria may be competent to take up extracellular DNA, may be donor bacteria, or may be members of a library. The present invention also features methods of creating and utilizing such bacteria.
    Type: Application
    Filed: September 7, 2012
    Publication date: August 7, 2014
    Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.
    Inventors: David Bramhill, Uwe Mamat
  • Publication number: 20140154738
    Abstract: The present invention provides genetically engineered strains of Pichia capable of producing proteins with reduced glycosylation. In particular, the genetically engineered strains of the present invention are capable of expressing either or both of an ?-1,2-mannosidase and glucosidase II. The genetically engineered strains of the present invention can be further modified such that the OCH1 gene is disrupted. Methods of producing glycoproteins with reduced glycosylation using such genetically engineered stains of Pichia are also provided.
    Type: Application
    Filed: January 10, 2014
    Publication date: June 5, 2014
    Applicants: VIB, VZW, UNIVERSITEIT GENT, RESEARCH CORPORATION TECHNOLOGIES, INC.
    Inventors: Roland Contreras, Nico L.M. Callewaert, Steven C.J. Geysens
  • Patent number: 8663971
    Abstract: The present invention provides genetically engineered strains of Pichia capable of producing proteins with reduced glycosylation. In particular, the genetically engineered strains of the present invention are capable of expressing either or both of an ?-1,2-mannosidase and glucosidase II. The genetically engineered strains of the present invention can be further modified such that the OCH1 gene is disrupted. Methods of producing glycoproteins with reduced glycosylation using such genetically engineered stains of Pichia are also provided.
    Type: Grant
    Filed: April 16, 2009
    Date of Patent: March 4, 2014
    Assignees: VIB, VZW, Research Corporation Technologies, Inc., Universiteit Gent
    Inventors: Roland Contreras, Nico L. M. Callewaert, Steven C. J. Geysens
  • Publication number: 20130316953
    Abstract: The present invention is directed to the use of compounds of the formula: for treating pain, in particular neuropathic pain, bipolar disease and migraine headaches.
    Type: Application
    Filed: July 29, 2013
    Publication date: November 28, 2013
    Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.
    Inventor: Robert H. Harris
  • Patent number: 8519183
    Abstract: The present invention is directed to the use of compounds of the formula: for treating pain, in particular neuropathic pain, bipolar disease and migraine headaches.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: August 27, 2013
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Robert H. Harris
  • Publication number: 20130189247
    Abstract: The present invention relate to small binding proteins comprising two or more protein domains derived from a CH2 domain or CH2-like domain of an immunoglobulin in which the CH2 domains have been altered to recognize one or more target proteins and, in some embodiments, retain, or have modified, certain secondary effector functions.
    Type: Application
    Filed: February 11, 2011
    Publication date: July 25, 2013
    Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.
    Inventors: David Bramhill, Kurt R. Gehlsen, Dimiter S. Dimitrov, Rui Gong
  • Patent number: 8440456
    Abstract: The present invention provides the genome sequence of Pichia pastoris and manually curated annotation of protein-coding genes. The invention provides novel nucleic acids, proteins, and related expression vectors useful for genetic engineering of methylotrophic yeast strains, as well as engineered methylotrophic yeast strains particularly Pichia pastsoris, and use thereof for recombinant production of heterologous proteins including glycoproteins suitable for use in mammals including humans.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: May 14, 2013
    Assignees: VIB, VZW, Universiteit Gent, Research Corporation Technologies, Inc.
    Inventors: Nico Callewaert, Kristof De Schutter, Petra Tiels, Yao-Cheng Lin
  • Patent number: 8354268
    Abstract: The present invention provides genetically engineered strains of Pichiacapable of producing proteins with reduced glycosylation. In particular, the genetically engineered strains of the present invention are capable of expressing either or both of an ?-1,2-mannosidase and glucosidase II. The genetically engineered strains of the present invention can be further modified such that the OCH1 gene is disrupted. Methods of producing glycoproteins with reduced glycosylation using such genetically engineered stains of Pichia are also provided.
    Type: Grant
    Filed: September 25, 2003
    Date of Patent: January 15, 2013
    Assignees: VIB, VZW, Research Corporation Technologies, Inc., Universiteit Gent
    Inventors: Roland Contreras, Nico L. M. Callewaert, Steven C. J. Geysens
  • Patent number: 8303964
    Abstract: The present invention provides non-toxic Gram-negative bacteria. In particular, the present invention provides viable Gram-negative bacteria (e.g., E. coli) substantially lacking lipopolysaccharide (LPS, endotoxin) within the outer membrane. The present invention further provides methods of generating viable non-toxic Gram-negative bacteria and uses thereof. The present invention also provides compositions and methods for inducing immune responses and for researching and developing therapeutic agents.
    Type: Grant
    Filed: January 19, 2007
    Date of Patent: November 6, 2012
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Ronald Wesley Woodard, Timothy Charles Meredith, Parag Aggarwal
  • Patent number: 8263741
    Abstract: The present invention provides a fibronectin type III (Fn3) molecule, wherein the Fn3 contains a stabilizing mutation. The present invention also provides Fn3 polypeptide monobodies, nucleic acid molecules encoding monobodies, and variegated nucleic acid libraries encoding such monobodies. Also provided are methods of preparing a Fn3 polypeptide monobody, and kits to perform the methods.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: September 11, 2012
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Shohei Koide
  • Patent number: 8258265
    Abstract: The present invention provides modified fibronectin type III (Fn3) molecules, and nucleic acid molecules encoding the modified Fn3 molecules. Also provided are methods of preparing these molecules, and kits to perform the methods.
    Type: Grant
    Filed: August 30, 2007
    Date of Patent: September 4, 2012
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Shohei Koide
  • Publication number: 20120029174
    Abstract: The present invention provides methods for effectively and efficiently converting methylotrophic yeast's heterogeneous high mannose-type N-glycosylation to mammalian-type N-glycosylation by disruption of an endogenous glycosyltransferase gene (OCH1) and step-wise introduction of heterologous glycosidase and glycosyltransferase activities. Each engineering step includes a number of stages: transformation with an appropriate vector, cultivation of a number of transformants, performance of sugar analysis and heterologous protein expression analysis, and selection of a desirable clone. The selected clone is then subjected to the next engineering step.
    Type: Application
    Filed: September 23, 2011
    Publication date: February 2, 2012
    Applicants: VIB, VZW, Research Corporation Technologies, Inc., Universiteit Gent
    Inventors: Nico Callewaert, David A. Wiersma
  • Patent number: 8058053
    Abstract: The present invention relates to methods and genetically engineered methylotrophic yeast strains for producing glycoproteins with mammalian-like glycosylation. The present invention also relates to vectors useful for generating methylotrophic yeast strains capable of producing glycoproteins with mammalian-like glycosylation. Glycoproteins produced from the genetically engineered methylotrophic yeast strains are also provided.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: November 15, 2011
    Assignees: VIB, VZW, Universiteit Gent, Research Corporation Technologies, Inc.
    Inventors: Roland Contreras, Nico L. M. Callewaert, Wouter Vervecken, Vladimir Kaigorodov
  • Publication number: 20110092374
    Abstract: The present invention provides methods for effectively and efficiently converting methylotrophic yeast's heterogeneous high mannose-type N-glycosylation to mammalian-type N-glycosylation by disruption of an endogenous glycosyltransferase gene (OCH1) and step-wise introduction of heterologous glycosidase and glycosyltransferase activities. Each engineering step includes a number of stages: transformation with an appropriate vector, cultivation of a number of transformants, performance of sugar analysis and heterologous protein expression analysis, and selection of a desirable clone. The selected clone is then subjected to the next engineering step.
    Type: Application
    Filed: October 18, 2010
    Publication date: April 21, 2011
    Applicants: VIB, VZW, UNIVERSITEIT GENT, RESEARCH CORPORATION TECHNOLOGIES, INC.
    Inventors: Nico Callewaert, David A. Wiersma
  • Publication number: 20100273716
    Abstract: The present invention is directed to the use of compounds of the formula: for treating pain, in particular neuropathic pain, bipolar disease and migraine headaches.
    Type: Application
    Filed: July 1, 2010
    Publication date: October 28, 2010
    Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.
    Inventor: Robert H. Harris
  • Publication number: 20100267084
    Abstract: The present invention provides genetically engineered strains of Pichia capable of producing proteins with reduced glycosylation. In particular, the genetically engineered strains of the present invention are capable of expressing either or both of an ?-1,2-mannosidase and glucosidase II. The genetically engineered strains of the present invention can be further modified such that the OCH1 gene is disrupted. Methods of producing glycoproteins with reduced glycosylation using such genetically engineered stains of Pichia are also provided.
    Type: Application
    Filed: April 16, 2009
    Publication date: October 21, 2010
    Applicants: VIB, VZW, RESEARCH CORPORATION TECHNOLOGIES, INC.
    Inventors: Roland Contreras, Nico L. M. Callewaert, Steven C. J. Geysens
  • Patent number: 7811233
    Abstract: A method and system for imaging a sample. The method includes the steps of generating an ultrasonic signal, directing the signal into a sample, which signal is distorted and contains a first order and higher order component signals at first and higher frequencies respectively. The received distorted signal is processed, and an image is formed, and then displayed, from the sum of the first order and second order component signals of the received distorted signal.
    Type: Grant
    Filed: December 24, 2008
    Date of Patent: October 12, 2010
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Ted Christopher
  • Patent number: 7772427
    Abstract: The present invention relates to the use of compounds of the formula for treating obsessive compulsive neurosis.
    Type: Grant
    Filed: January 10, 2007
    Date of Patent: August 10, 2010
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Robert H. Harris